How does a single blood test in 2012 turn into a national research infrastructure by 2026?
That year, Professor Georgios Patrinos became the first Greek citizen to have his complete genome sequenced — at a time when whole-genome sequencing remained rare practice worldwide. The results were more personal than he expected: 187 variants linked to hereditary cancer, discovered while he was preparing a lecture on cancer genomics.
That experience became the foundation of “Genome of Greece,” the national genomic database he had already launched in 2010 while leading the Laboratory of Pharmacogenomics and Personalized Therapy at the University of Patras. At the time, the field of genetics in Greece faced considerable structural challenges: the absence of a recognized medical specialty in genetics, limited regulatory oversight, inconsistent laboratory standards, and minimal integration of pharmacogenomics into university curricula.
Fifteen years on, the initiative offers a meaningful case study in building national research infrastructure:
- 187 cancer-associated variants were identified in Professor Patrinos’s own genome. Subsequent research by his team found that none were capable of causing disease on their own — a finding echoed in a related study of 570 variants across two families in Greece and Malta, of which only two carried genuine pathogenic potential. The result underscored the importance of qualified genetic counseling in interpreting such findings.
- ~600 individuals have had their genomes sequenced through the program, spanning the general population and patient cohorts affected by ALS, thalassemia, and celiac disease, with data fully anonymized and stored offline.
- 2024 integration into the European “Genome of Europe” initiative, with plans to sequence a further 2,500 genomes as part of joint clinical studies.
- 30% reduction in adverse drug reactions, demonstrated in a pan-European clinical trial (2017–2020, 7,000 patients across seven countries) published in The Lancet. Among psychiatric patients in Greece specifically, side effects fell by 34% and hospital readmissions by 41%.
“Genome of Greece” now operates under the auspices of the Hellenic Pasteur Institute, where Professor Patrinos serves as General Director. Beyond its scientific database, the initiative has contributed to training new researchers, embedding personalized medicine within university teaching, and advancing public understanding of genetics — through programs such as Hellenic DNA Day, which engaged more than 300 schools, and this year’s Human Genome Meeting 2026, hosted in Athens.
Professor Patrinos remains measured about the current limits of the science: the function of only around 8,000 of the roughly 20,000 human genes is presently understood. As he puts it, drawing definitive conclusions from today’s genomic knowledge would be premature — though findings that offer little insight now may prove significant for future generations.
Notable gaps persist: the absence of a comprehensive regulatory framework for genetic testing in Greece, unequal access to genetic services, and constrained funding. Nonetheless, the trajectory over the past fifteen years illustrates how a single sequencing test can grow into a national research infrastructure with a role in shaping European genomics policy.
#PersonalizedMedicine #Genomics #GenomeOfGreece #HellenicPasteurInstitute #PrecisionMedicine